|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Meyerhardt JA, Li L, Sanoff HK, Carpenter
W IV and Schrag D: Effectiveness of bevacizumab with first-line
combination chemotherapy for Medicare patients with stage IV
colorectal cancer. J Clin Oncol. 30:608–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kuznicki J and Filipek A: Purification and
properties of a novel Ca2+-binding protein (10.5 kDa)
from Ehrlich-ascites-tumour cells. Biochem J. 247:663–667.
1987.PubMed/NCBI
|
|
4.
|
Lesniak W, Slomnicki LP and Filipek A:
S100A6 - new facts and features. Biochem Biophys Res Commun.
390:1087–1092. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Breen EC and Tang K: Calcyclin (S100A6)
regulates pulmonary fibroblast proliferation, morphology, and
cytoskeletal organization in vitro. J Cell Biochem. 88:848–854.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Hwang R, Lee EJ, Kim MH, et al: Calcyclin,
a Ca2+ ion-binding protein, contributes to the anabolic
effects of simvastatin on bone. J Biol Chem. 279:21239–21247.
2004.
|
|
7.
|
Ohuchida K, Mizumoto K, Ishikawa N, et al:
The role of S100A6 in pancreatic cancer development and its
clinical implication as a diagnostic marker and therapeutic target.
Clin Cancer Res. 11:7785–7793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Nedjadi T, Kitteringham N, Campbell F, et
al: S100A6 binds to annexin 2 in pancreatic cancer cells and
promotes pancreatic cancer cell motility. Br J Cancer.
101:1145–1154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Luo X, Sharff KA, Chen J, He TC and Luu
HH: S100A6 expression and function in human osteosarcoma. Clin
Orthop Relat Res. 466:2060–2070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Mbeunkui F, Metge BJ, Shevde LA and
Pannell LK: Identification of differentially secreted biomarkers
using LC-MS/MS in isogenic cell lines representing a progression of
breast cancer. J Proteome Res. 6:2993–3002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Leclerc E, Fritz G, Weibel M, Heizmann CW
and Galichet A: S100B and S100A6 differentially modulate cell
survival by interacting with distinct RAGE (receptor for advanced
glycation end products) immunoglobulin domains. J Biol Chem.
282:31317–31331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Donato R: S100: a multigenic family of
calcium-modulated proteins of the EF-hand type with intracellular
and extracellular functional roles. Int J Biochem Cell Biol.
33:637–668. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Heizmann CW, Fritz G and Schafer BW: S100
proteins: structure, functions and pathology. Front Biosci.
7:d1356–d1368. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Donato R: Intracellular and extracellular
roles of S100 proteins. Microsc Res Tech. 60:540–551. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Komatsu K, Andoh A, Ishiguro S, et al:
Increased expression of S100A6 (Calcyclin), a calcium-binding
protein of the S100 family, in human colorectal adenocarcinomas.
Clin Cancer Res. 6:172–177. 2000.PubMed/NCBI
|
|
16.
|
Alvarez-Chaver P, Rodriguez-Pineiro AM,
Rodriguez-Berrocal FJ, Martinez-Zorzano VS and Paez de la Cadena M:
Identification of hydrophobic proteins as biomarker candidates for
colorectal cancer. Int J Biochem Cell Biol. 39:529–540. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kilanczyk E, Graczyk A, Ostrowska H,
Kasacka I, Lesniak W and Filipek A: S100A6 is transcriptionally
regulated by beta-catenin and interacts with a novel target, lamin
A/C, in colorectal cancer cells. Cell Calcium. 51:470–477. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Tothova V and Gibadulinova A: S100P, a
peculiar member of S100 family of calcium-binding proteins
implicated in cancer. Acta Virol. 57:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ghavami S, Rashedi I, Dattilo BM, et al:
S100A8/A9 at low concentration promotes tumor cell growth via RAGE
ligation and MAP kinase-dependent pathway. J Leukoc Biol.
83:1484–1492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kwon CH, Moon HJ, Park HJ, Choi JH and
Park do Y: S100A8 and S100A9 promotes invasion and migration
through p38 mitogen-activated protein kinase-dependent NF-kappaB
activation in gastric cancer cells. Mol Cells. 35:226–234. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wu R, Duan L, Ye L, et al: S100A9 promotes
the proliferation and invasion of HepG2 hepatocellular carcinoma
cells via the activation of the MAPK signaling pathway. Int J
Oncol. 42:1001–1010. 2013.PubMed/NCBI
|
|
23.
|
Nakashima M, Sakai T, Hiraiwa H, et al:
Role of S100A12 in the pathogenesis of osteoarthritis. Biochem
Biophys Res Commun. 422:508–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Jin Q, Chen H, Luo A, Ding F and Liu Z:
S100A14 stimulates cell proliferation and induces cell apoptosis at
different concentrations via receptor for advanced glycation end
products (RAGE). PloS One. 6:e193752011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Duan L, Wu R, Ye L, et al: S100A8 and
S100A9 are associated with colorectal carcinoma progression and
contribute to colorectal carcinoma cell survival and migration via
Wnt/beta-catenin pathway. PloS One. 8:e620922013. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zou Z, Wang H, Li Y, et al: Prokaryotic
expression of recombinant protein HS100A6 and its biological
effects on human osteosarcoma cell line 143B. China Biotechnol.
32:1–7. 2012.
|
|
27.
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
29.
|
Berta GN, Ghezzo F, D’Avolio A, et al:
Enhancement of calcyclin gene RNA expression in squamous cell
carcinoma of the oral mucosa, but not in benign lesions. J Oral
Pathol Med. 26:206–210. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Vimalachandran D, Greenhalf W, Thompson C,
et al: High nuclear S100A6 (Calcyclin) is significantly associated
with poor survival in pancreatic cancer patients. Cancer Res.
65:3218–3225. 2005.PubMed/NCBI
|
|
31.
|
Yang YQ, Zhang LJ, Dong H, et al:
Upregulated expression of S100A6 in human gastric cancer. J Dig
Dis. 8:186–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Fullen DR, Garrisi AJ, Sanders D and
Thomas D: Expression of S100A6 protein in a broad spectrum of
cutaneous tumors using tissue microarrays. J Cutan Pathol. 35(Suppl
2): 28–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Slomnicki LP and Lesniak W: S100A6
(calcyclin) deficiency induces senescence-like changes in cell
cycle, morphology and functional characteristics of mouse NIH 3T3
fibroblasts. J Cell Biochem. 109:576–584. 2010.
|
|
34.
|
Simone C: Signal-dependent control of
autophagy and cell death in colorectal cancer cell: the role of the
p38 pathway. Autophagy. 3:468–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Wei SC, Tsao PN, Weng MT, Cao Z and Wong
JM: Flt-1 in colorectal cancer cells is required for the tumor
invasive effect of placental growth factor through a p38-MMP9
pathway. J Biomed Sci. 20:392013. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Ragusa M, Statello L, Maugeri M, et al:
Specific alterations of the microRNA transcriptome and global
network structure in colorectal cancer after treatment with
MAPK/ERK inhibitors. J Mol Med. 90:1421–1438. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Mohan SK, Gupta AA and Yu C: Interaction
of the S100A6 mutant (C3S) with the V domain of the receptor for
advanced glycation end products (RAGE). Biochem Biophys Res Commun.
434:328–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Heijmans J, Buller NV, Hoff E, et al: Rage
signalling promotes intestinal tumourigenesis. Oncogene.
32:1202–1206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Sasahira T, Akama Y, Fujii K and Kuniyasu
H: Expression of receptor for advanced glycation end products and
HMGB1/amphoterin in colorectal adenomas. Virchows Arch.
446:411–415. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kuniyasu H, Chihara Y and Takahashi T:
Co-expression of receptor for advanced glycation end products and
the ligand amphoterin associates closely with metastasis of
colorectal cancer. Oncol Rep. 10:445–448. 2003.PubMed/NCBI
|
|
41.
|
Hofmann MA, Drury S, Fu C, et al: RAGE
mediates a novel proinflammatory axis: a central cell surface
receptor for S100/calgranulin polypeptides. Cell. 97:889–901. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Ichikawa M, Williams R, Wang L, Vogl T and
Srikrishna G: S100A8/A9 activate key genes and pathways in colon
tumor progression. Mol Cancer Res. 9:133–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
